Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

Cushing's Syndrome Clinical Trial

Official title:

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03817840
• Other study ID #: AAAR7901
• Status: Completed
• Start date: July 16, 2018
• Est. completion date: July 1, 2021

Study information

• Verified date: May 2024
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.

Description:

Cushing's disease (CD) is a disorder of chronic glucocorticoid (GC) excess that gives rise to a constellation of metabolic comorbidities and to a distinct lipodystrophic body habitus characterized by central adiposity, extremity wasting, and the accumulation of supraclavicular (SC) and dorsocervical (DC) fat in the region where human brown and beige adipose tissue is known to be concentrated. In spite of the recognized thermogenic capacity of select cervical adipocytes, the potential impact of lipomatous alterations in this depot on energy balance and metabolism in CD is unknown. To our knowledge, the "buffalo hump" and the supraclavicular fat pads - which are a sensitive physical finding for CD, have never been phenotypically characterized and the mechanisms underlying the GC mediated development of fat in these depots and the associated metabolic complications have not been explored in humans. The proposed research will advance our understanding of Cushing's lipodystrophy and its metabolic complications. Furthermore, it may lead to the identification of novel mediators and targetable pathways to attenuate the adverse effects of hypercortisolism on body composition and metabolism in CD, as well as in the significant population of patients treated with chronic GCs for an array of other clinical conditions. These findings may have important implications not only for those with Cushing's disease, but for the millions of Americans who are treated with chronic glucocorticoids for an array of clinical conditions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: July 1, 2021
• Est. primary completion date: July 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Aged 18-70 yrs

2. Body mass index (BMI) <35 kg/m2

3. Urine free cortisol (UFC) =150ug/d

4. Pituitary tumor >6mm on MRI or an inferior petrosal sinus sampling with central to peripheral plasma adrenocorticotropic hormone (ACTH) gradient

5. Normal renal and thyroid function

6. HbA1c =8.0.

Exclusion Criteria:

1. Smoking

2. Alcohol >2 drinks/day

3. Uncontrolled hypertension

4. HIV given potential for lipodystrophic confounding

5. Pregnancy and nursing

6. Use of beta-blockers, ß-adrenergic or diabetes medications other than insulin

7. History of claustrophobia or difficulty lying flat

8. In-dwelling metal hardware.

Related Conditions & MeSH terms

• ACTH-Secreting Pituitary Adenoma
• Cushing Syndrome
• Cushing's Syndrome
• Lipodystrophy
• Pituitary ACTH Hypersecretion

Intervention

Procedure:
• Treatment of Cushing's
Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism

Locations

Country	Name	City	State
United States	Columbia University Neuroendocrine Unit	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	New York Obesity and Nutrition Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Energy Expenditure	Resting energy expenditure (REE) will be measured by whole room indirect calorimetry prior to and following cure of Cushing's Disease (CD).	Change from baseline REE at 3 months post-treatment
Secondary	Total body adipose tissue volume	Whole body MRI will be utilized to measure total body adipose tissue volume	Change in total body adipose tissue volume from baseline at 3 months post-treatment